Santarus Inc.
3721 Valley Centre Drive
Suite 400
San Diego,
CA 92130
Telefone: 858-314-5700
Fax: 858-314-5701
Web Site: http://www.santarus.com
| Santarus, Inc., a specialty pharmaceutical company, engages in acquiring, developing, and commercializing proprietary products that treat upper gastrointestinal diseases and disorders. Its products include Zegerid capsules and powder for oral suspension, which are proprietary immediate-release formulations that combine antacids and omeprazole (a proton pump inhibitor) to treat upper gastrointestinal diseases and disorders, including gastroesophageal reflux disease (GERD); and Glumetza for the treatment of type 2 diabetes. The company is also developing a Zegerid tablet formulation, Budesonide MMX for the treatment of mild or moderate active ulcerative colitis, and Rifamycin SV MMX for the treatment of travelers diarrhea. It has strategic alliances with Schering-Plough to develop, manufacture, and sell Zegerid brand OTC products in the lower dosage strength of 20 mg of omeprazole in the United States and Canada; GlaxoSmithKline to develop, manufacture, and commercialize prescription and OTC products in approximately 100 countries, including in Africa, Asia, the Middle-East, and Central and South America; and Cosmo Technologies, Ltd, which grants Santarus exclusive rights to develop and commercialize Budesonide MMX and Rifamycin SV MMX for the United States market. The company sells its products to wholesale distributors in the pharmaceutical industry. Santarus was founded in 1996 and is based in San Diego, California. |
|
| Principais estatísticas | Mais da Reuters
Descrição expandida da empresa |
| |
| | Pago | Exercido | Mr. Gerald T. Proehl , 51
Chief Exec. Officer, Pres and Exec. Director |
$
810.00K |
$
65.00K | Ms. Debra P. Crawford , 52
Chief Financial Officer, Principal Accounting Officer, Sr. VP, Sec. and Treasurer |
N/D
| N/D | Mr. William C. Denby III, 54
Sr. VP of Commercial Operations |
$
406.00K |
$
18.00K | Dr. E. David Ballard II, MD, 54
Sr. VP of Clinical Research and Medical Affairs |
$
412.00K | N/D | Ms. Carey J. Fox Esq., J.D., 41
Sr. VP and Gen. Counsel |
$
390.00K | N/D |
|
|
|
Somas desde
31-Dec-08
e valores de compensação são para o ano fiscal que termina nesta data. "Pago" é salário, bônus, etc. "Exercício" é o valor de ações exercidas durante o ano fiscal.
| |
|
Ajuda
0.01 (0.27%) 
Perfil
A Reuters oferece mais 
